Versameb to Present at the 2022 American Association for Cancer Research (AACR) Annual Meeting
· Developing RNA molecules which target multiple proteins in a single construct into cancer therapeutics
5 April 2022, Basel, Switzerland: Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, today announces it will present a poster entitled ‘Design of combinatory RNA molecules to simultaneously activate tumor immunity and target several signaling pathways in solid tumors’ on the 11th of April at the American Association of Cancer Research (AACR) Annual Meeting, taking place in New Orleans, USA on the 8 – 13 April 2022. [An e-poster will be made available online at 1 pm EDT, April 8, 2022].
The poster will present data on Versameb’s technology platform VERSagile which enables combinatorial approaches of nucleotide therapeutics that comprise an mRNA element covalently linked to up to three independent siRNA elements targeting various oncogenes. Such constructs allow a synchronized up- and down regulation of different proteins in parallel, which opens the opportunity to address up to four cancer targets within a single RNA molecule.
Versameb aims to develop mRNA combination constructs into cancer therapeutics that target several pro-tumorigenic pathways simultaneously with a single molecule overcoming hurdles of efficacy, resistance and tumor heterogeneity.
Title: Design of combinatory RNA molecules to simultaneously activate tumor immunity and target several signaling pathways in solid tumors
Session name and category: PO.ET01.05 - Drug Conjugates / Bispecific Antibodies, New Orleans Convention Center, Section 22
Authors: Petra Hillmann, Justin A. Selvaraj, Sina E. Zimmerli, Pascale G. Birrer, Claudia C. Bohnert, Klaas P. Zuideveld, Stefan J. Scherer, Friedrich Metzger
Date & Time: Monday, 11 April 2022, 09.00am – 12.30pm CDT
The abstract is available online via the AACR Annual Meeting website at https://www.abstractsonline.com/pp8/#!/10517/presentation/12265
Klaas Zuideveld, Chief Executive Officer of Versameb, said: “We are excited to be presenting at the American Association of Cancer Research to highlight Versameb’s truly differentiated approach to creating novel anti-tumor therapeutics, which we are actively progressing towards the clinic while advancing our VERSagile platform.”
Friedrich Metzger, Chief Scientific Officer, said: “Our data validate that combinatory RNA constructs can be developed into cancer and other therapeutics to overcome the limitations of current approaches to treating severe and debilitating diseases.”